Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.
| CEO: |
Frank Mathias |
| CFO: |
Lucinda (Lucy) Crabtree |
| Chairman: |
Roch Doliveux |
| Non-Executive Director: |
Robert Ghenchev, Peter Soelkner, Laurence Espinasse |
| Senior Independent Director: |
Dame Kay Davies |
| Vice Chairman: |
Stuart Henderson |
| Independent Non-Executive Director: |
Heather Preston, Leone Patterson, Namrata P Patel |
| Address: |
Windrush Court, Transport Way, Oxford, United Kingdom |
| Phone: |
+44 (0) 1865 783 000 |
| Fax: |
+44 (0) 1865 783 001 |
| Website: |
http://www.oxb.com/ |
| Email: |
|